# Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

> **NCT00995930** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 189 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Atherosclerosis
- Prediabetic State

## Interventions

- **DRUG:** ACZ885
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00995930
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2015-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00995930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00995930, "Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00995930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*